Visit our COVID-19 and Preeclampsia resource page. Click Here

Last Updated on June 15, 2015

Advancing Biomarkers to Screen and Diagnose Preeclampsia: A Report to Stakeholders

In December 2012, the Preeclampsia Foundation convened stakeholders from industry, academia, FDA, laboratories, patients and clinicians to assess the state of biomarkers for preeclampsia, identify barriers and brainstorm strategies to overcome those challenges.  This report includes background on the state of molecular biomarkers for preeclampsia screening and diagnosis, identification of the needs and challenges facing the field, the proceedings and participants of the Biomarkers Consortium, and the resulting calls to action, broken out by stakeholders (research and academia, manufacturers and laboratories, clinical, regulatory, and patient organizations).

Read the complete report of the first Biomarkers Consortium.

Related Articles